Avadel Pharmaceuticals plc
http://www.avadel.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avadel Pharmaceuticals plc
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Expectations Of Lumakras ESMO Late-Breaker Build As Roche Plays KRAS Catch-Up
Amgen secured a last-minute slot as a late-breaker study with Lumakras, appearing to give it the upper hand on rival Mirati once again.
Finance Watch: Recent Upswing Turns Down, But Two Small IPOs Launch
Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Drug Delivery
- Controlled Release
- Macromolecule
- Other Names / Subsidiaries
-
- Avadel Specialty Pharmaceuticals, LLC
- Éclat Pharmaceuticals, L.L.C.
- FSC Pediatrics, Inc.
- FSC Therapeutics, LLC
- FSC Laboratories, Inc.
- FSC Holdings, LLC
- Flamel Technologies